A Beta-only IL-2 ImmunoTherapY Study
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell CarcinomaTriple Negative Breast CancerNon-Small Cell Lung Cancer SquamousNon-Small Cell Lung Cancer Non-squamousColorectal Cancer (MSI-H)Gastric CancerCervical CancerBasal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Medicenna Therapeutics, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT05086692
- Locations
- 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇦🇺University of the Sunshine Coast, Buderim, Queensland, Australia
🇮🇪Mater Misericordiae University Hospital, Dublin, Ireland
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase 2
Completed
- Conditions
- GlioblastomaGlioblastoma MultiformeGrade IV GliomaGrade IV Astrocytoma
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Medicenna Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02858895
- Locations
- 🇺🇸
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath